| 1 |
Ungar B, Malickova K, Hanžel J, Abu-Arisha M, Paul S, Rocha C, Ben-Shatach Z, Abitbol CM, Haj-Natour O, Selinger L, Yavzori M, Fudim E, Picard O, Shoval I, Eliakim R, Kopylov U, Magro F, Roblin X, Chowers Y, Drobne D, Lukas M, Ben-Horin S. Dose-optimization for loss-of-response to vedolizumab - pharmacokinetics and immune mechanisms. J Crohns Colitis 2021:jjab067. [PMID: 33837762 DOI: 10.1093/ecco-jcc/jjab067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 2 |
Veny M, Garrido-Trigo A, Corraliza AM, Masamunt MC, Bassolas-Molina H, Esteller M, Arroyes M, Tristán E, Fernández-Clotet A, Ordás I, Ricart E, Esteve M, Panés J, Salas A. Dissecting Common and Unique Effects of Anti-α4β7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis. J Crohns Colitis 2021;15:441-52. [PMID: 32926095 DOI: 10.1093/ecco-jcc/jjaa178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 3 |
Zundler S, Becker E, Schulze LL, Neurath MF. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances. Gut 2019;68:1688-700. [PMID: 31127023 DOI: 10.1136/gutjnl-2018-317977] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 18.3] [Reference Citation Analysis]
|
| 4 |
RoŽanc J, Finšgar M, Maver U. Progressive use of multispectral imaging flow cytometry in various research areas. Analyst 2021;146:4985-5007. [PMID: 34337638 DOI: 10.1039/d1an00788b] [Reference Citation Analysis]
|
| 5 |
Tong X, Zheng Y, Li Y, Xiong Y, Chen D. Soluble ligands as drug targets for treatment of inflammatory bowel disease. Pharmacol Ther 2021;226:107859. [PMID: 33895184 DOI: 10.1016/j.pharmthera.2021.107859] [Reference Citation Analysis]
|
| 6 |
Cox D. How not to discover a drug - integrins. Expert Opin Drug Discov 2021;16:197-211. [PMID: 32921156 DOI: 10.1080/17460441.2020.1819234] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
D'Amico F, Danese S, Peyrin-Biroulet L. Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins? Expert Opin Biol Ther 2020;20:353-61. [PMID: 31951748 DOI: 10.1080/14712598.2020.1717465] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 8 |
Zundler S, Wiendl M, Neurath MF. Anti-trafficking agents in the treatment of inflammatory bowel disease. Current Opinion in Gastroenterology 2019;35:499-506. [DOI: 10.1097/mog.0000000000000579] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 9 |
Kaplon H, Muralidharan M, Schneider Z, Reichert JM. Antibodies to watch in 2020. MAbs 2020;12:1703531. [PMID: 31847708 DOI: 10.1080/19420862.2019.1703531] [Cited by in Crossref: 219] [Cited by in F6Publishing: 193] [Article Influence: 219.0] [Reference Citation Analysis]
|
| 10 |
Moreno LO, Fernández-tomé S, Abalo R. Biological Treatments in Inflammatory Bowel Disease: A Complex Mix of Mechanisms and Actions. Biologics 2021;1:189-210. [DOI: 10.3390/biologics1020012] [Reference Citation Analysis]
|
| 11 |
Carballido JM, Regairaz C, Rauld C, Raad L, Picard D, Kammüller M. The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases. Front Immunol 2020;11:472. [PMID: 32296421 DOI: 10.3389/fimmu.2020.00472] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 12 |
Barreto de Albuquerque J, Mueller C, Gungor B. Tissue-Resident T Cells in Chronic Relapsing-Remitting Intestinal Disorders. Cells 2021;10:1882. [PMID: 34440651 DOI: 10.3390/cells10081882] [Reference Citation Analysis]
|
| 13 |
Lutter L, Roosenboom B, Brand EC, Ter Linde JJ, Oldenburg B, van Lochem EG, Horje Talabur Horjus CS, van Wijk F. Homeostatic Function and Inflammatory Activation of Ileal CD8+ Tissue-Resident T Cells Is Dependent on Mucosal Location. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00137-5. [PMID: 34224909 DOI: 10.1016/j.jcmgh.2021.06.022] [Reference Citation Analysis]
|
| 14 |
Oftedal BE, Wolff ASB. New era of therapy for endocrine autoimmune disorders. Scand J Immunol 2020;92:e12961. [PMID: 32853446 DOI: 10.1111/sji.12961] [Reference Citation Analysis]
|
